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Targeting lipid metabolism (biosynthesis and catabolism)
associated with human diseases and pathogens with thera-
peuticshasgainedmuchmomentuminrecentyears.Thishas
come about in part due to the wide availability of sequenced
genomes, the advancement in analytical techniques such as
mass spectrometry and deep sequencing, and the increased
understanding of signaling molecules. Collectively, this has
advanced the knowledge of lipid metabolism for transla-
tional purposes, that is, diagnosis or treatment, and the pa-
pers and reviews in this special issue highlight some of these
aspects.
One review in this issue by S. Young et al. outlines the
major pathways in eukaryotic sphingolipid metabolism and
catabolism and discusses these in relation to the possibilities
of their therapeutic intervention against cancers, Alzheimer’s
disease, inherited diseases, and numerous important human
pathogens.
Such a pathogenic disease is leishmaniases, which is the
subject of the paper by H. Ali et al., who investigate the re-
liance of old and new world Leishmania species on host
sphingolipidsandhowaninfectionmayormaynotinﬂuence
host sphingolipid biosynthesis.
Another review in this issue addresses the link between
serum triglyceride levels caused by a dysregulation of lipo-
protein lipase and the risk of development of various can-
cers, atherosclerosis, chylomicronemia, obesity, and type 2
diabetes. S. Takasu et al. conclude that as lipoprotein lipase
plays important roles in many of these conditions and as
such it is appropriate to treat it as a general target for chemo-
preventive and chemotherapeutic agents.
This approach is nicely highlighted by the paper by R.
Noriega-Cisneros et al., who investigate the eﬀect of chronic
administration of ethanolic extract of Eryngium carlinae in
serum of streptozotocin-induced diabetic rats. They clearly
show reduced levels of creatinine, uric acid, total cholesterol
and triglycerides, thus as a general approach this could be
used to reduce hyperlipidemia related to cardiovascular risk
in diabetes mellitus.
In a related area, Saldanha et al. look at the behavior of
human erythrocyte aggregation in presence of autologous li-
poprotein, ﬁnding that human blood aliquots enriched with
their own LDL-C and HDL-C showed higher levels of ery-
throcyte aggregation compared to controls.
N. Nikoli´ c et al. show in their paper that overexpression
of peroxisome proliferator-activated receptor γ coactivator-
1αincreasesoxidativecapacityofhumanskeletalmusclecells
byimprovinglipidmetabolism,thusincreasingexpressionof
genes involved in regulation of mitochondrial function and
biogenesis and decreasing expression of the fast ﬁber-type
gene marker MHCIIa. They conclude that obesity and obe-
sity-related diseases could be therapeutically targeted by in-
creasing expression of peroxisome proliferator-activated re-
ceptor γ coactivator-1α.
While M. Cahova et al., in their study on liver lysosomal
lipase activity, conclude that overproduction of diacylglyc-
erol may represent the causal link between high-fat die-in-
duced hepatic triacylglycerol accumulation and hepatic in-
sulin resistance via PKCε activation.
Onapersonalnote,Iwouldliketohighlightthatthrough
my own research on protozoan parasites and that with var-
ious collaborators studying a wide variety of human patho-
gens and model systems for human diseases, mitochondrial
dysfunction as a result of not maintaining its lipid home-
ostasis seems to be a leading cause for many of downstream2 Biochemistry Research International
aﬀects.Thus,Iwouldsuggestabetterunderstandingofmito-
chondriallipidmetabolism(bothbiosyntheticandcatabolic)
will aid the development of eﬀective novel therapeutics and
diagnostics in the future.
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